Introduction
============

Major improvements in neonatal survival have been observed in the last ten years, particularly at low gestational age.[@b1-opth-11-387] Retinopathy of prematurity (ROP) is a proliferative disorder of immature retinal vasculature with multifactorial etiology.[@b2-opth-11-387] ROP develops in 16% of all premature births, the figure rising to around 60% of infants weighing \<1,500 g at birth and 65% for infants \<1,250 g. Some studies suggest that as smaller and younger babies are surviving, its incidence is increasing. However, better understanding of screening and management of these babies have resulted in a decrease in its incidence.[@b3-opth-11-387] Both oxygen-regulated and non-oxygen-regulated factors contribute to normal vascular development and retinal neovascularization. Vascular endothelial growth factor (VEGF) is an important oxygen-regulated factor, while non-oxygen-regulated growth factor is insulin-like growth factor-I (IGF-I).[@b4-opth-11-387] The initial phase of retinal vessel growth retardation occurs from birth to postmenstrual age of \~30--32 weeks. Oxygen plays a critical role in this process. Hypoxia and hyperoxia, by the high levels of supplemental oxygen the infant may receive in the neonatal intensive care unit (NICU), inhibit production of growth factors, such as VEGF, which causes cessation of normal retinal growth, and vessels constriction with a potential for vaso-obliteration of new immature vessels, resulting in tissue hypoxia that releases factors to stimulate new retinal blood vessel growth, a process called neovascularization (Phase II).[@b5-opth-11-387]

Apelin is a pro-inflammatory adipocyte-derived factor that participates in vascular wall inflammation. It was identified in 1998 as an endogenous ligand of the human orphan G protein-coupled receptor, APJ.[@b6-opth-11-387] Apelin receptor is expressed in several cell types.[@b7-opth-11-387] The angiogenic activity is the consequence of apelin action on the proliferation and migration of the endothelial cells. Apelin expression is upregulated during new vessels formation and downregulated following vessels stabilization.[@b8-opth-11-387]

The aim of this study is to evaluate the role of serum apelin in ROP.

Patients and methods
====================

This is a prospective observational case--control study. It included 82 infants with a gestational age \<32 weeks and a birth weight of ≤1,500 g. The infants were screened for ROP at NICU, KJO Hospital, Saudi Arabia, during January 2014--March 2016.

Thirty-eight (20 males and 18 females) with classified ROP completed our study group. Twelve preterm babies who died before first ophthalmological examination and five preterm babies with multiple congenital anomalies were excluded from this study. Twenty-seven preterm neonates who did not develop ROP (16 males and 11 females) were studied as control group.

Ethical approval was obtained from the institutional review board of KJO Hospital, Saudi Arabia, and a written informed consent was provided by parents of all children prior to the study.

All the studied groups were subjected to detailed history taking, including identification, cause of admission, neonatal history, maternal history, and family history. Full clinical examinations include: Assessment -- gestational age was assessed using the date of the mother's last menstrual period and modified Ballard Score.[@b9-opth-11-387]Ophthalmological examination -- fundus examination was performed after pharmacological mydriasis starting 2 hours before the examination with cyclophrine eyedrops (combination of 2.5% phenylephrine and 1% cyclopentolate), applied three times at 30-minute intervals. Under topical anesthesia with boxinate eyedrops, an infantile eyelid speculum was applied. Using indirect binocular ophthalmoscope (Keeler Vantage^®^, Tampa, FL, USA), 20-diopter double aspheric Volk lens, the entire retina was carefully examined in all directions of gaze and with gentle pressure on the eyeball, using a scleral indenter for better visualization of the peripheral retina. The first examination was performed between 4 and 6 weeks of age or between 31 and 33 weeks of postmenstrual age. Follow-up examinations were made every week until the retinal vascularization was well into zone III. The presence or absence of the ROP plus disease, the zone, stage, and the extent of the ROP were recorded according to the international classification of ROP (stages 1--5).[@b10-opth-11-387]

Laboratory tests
----------------

1.  Routine laboratory investigations: Complete blood count, blood culture, C-reactive protein, liver and kidney functions, serum electrolytes, and arterial blood gases were monitored.

2.  Measurement of serum apelin peptide: Blood samples were obtained from studied 82 preterm babies twice: at birth (cord blood) and after 4--6 weeks. Two-milliliter venous blood sample was collected on ethylenediaminetetraacetic acid, centrifuged for 10 minutes at 5,000 rpm, and the plasma was separated. The serum was stored at −80°C in polypropylene tubes until the time of assay. Serum level of apelin peptide was measured using enzyme-linked immunosorbent assay kits (RayBiotech, Inc, Norcross, GA, USA. EIA Kit).[@b11-opth-11-387]

Statistical analysis
--------------------

Quantitative data were expressed as mean ± standard deviation (X ± SD). Qualitative data were expressed as frequency and percentage (%). Receiver operating characteristic (ROC) curve was used to define the best of serum apelin cutoff value.

Data were analyzed using Statistical Package for the Social Sciences (SPSS) version 18.0 (SPSS Inc., Chicago, IL, USA). A *P*-value \<0.05 was considered significant.

Results
=======

The demographic characteristics of the 38 ROP and 27 non-ROP infants were analyzed. The patient group included 38 neonates of gestational age ranging from 30 to 36 weeks (X ± SD: 34.37±1.29 weeks) and mean birth weight of 2.42±0.54 kg, compared with 27 age- and sex-matched preterm infants without ROP as control group ([Table 1](#t1-opth-11-387){ref-type="table"}).

Our study showed a highly significant negative correlation between stages of severity of ROP and Apgar score at 5 minutes of life in the patient group, while no correlation was found as regards mode of delivery, premature rupture of membranes, mechanical ventilation, pneumothorax, sepsis, blood transfusion, neonatal jaundice, and perinatal asphyxia. While, a significant positive correlation between the stages of ROP and oxygen therapy for \>7 days was observed (*P*\<0.05) ([Table 2](#t2-opth-11-387){ref-type="table"}).

A comparison of mean levels of serum apelin between the groups of patients and controls was undertaken. At the sampling time at birth, there were no significant differences between respective mean values in the two groups (*P*\>0.05). Measurements made at 4--6 weeks after birth showed higher mean concentrations of serum apelin in patients (*P*\<0.05) ([Table 3](#t3-opth-11-387){ref-type="table"}).

Serum apelin level cutoff value in samples taken at birth was 2.18 ng/mL, with sensitivity of 42.9%, specificity of 80%, positive predictive value of 68.2%, negative predictive value of 58.3%, and diagnostic accuracy of 59.1% ([Figures 1](#f1-opth-11-387){ref-type="fig"} and [2](#f2-opth-11-387){ref-type="fig"}). While the cutoff value of serum apelin levels taken at 4--6 weeks age was 2.7 ng/mL, with sensitivity of 62.9%, specificity of 80%, positive predictive value of 75.9%, negative predictive value of 68.3%, and diagnostic accuracy of 71% ([Figures 3](#f3-opth-11-387){ref-type="fig"} and [4](#f4-opth-11-387){ref-type="fig"}).

Discussion
==========

ROP is a disorder of the developing retina of low-birth-weight preterm infants that potentially leads to blindness in a small but significant percentage of those infants. In almost all term infants, the retina and retinal vasculature are fully developed, and ROP cannot occur; however, in preterm infants, the development of the retina, which proceeds from the optic nerve head anteriorly during the course of gestation, is incomplete, with the extent of the immaturity of the retina depending mainly on the degree of prematurity at birth.[@b12-opth-11-387] The rate of ROP in most premature infants has gone down greatly in developed countries over the past few decades due to better care in the NICU. However, more babies born very early are now able to survive, and these very premature infants are at the highest risk for ROP.[@b13-opth-11-387] Studies have shown that apelin was involved in vascular pathophysiology[@b6-opth-11-387] and act as an angiogenic factor stimulating retinal endothelial cells' proliferation, migration, and vascular tube formation.[@b14-opth-11-387],[@b15-opth-11-387]

In the current study, 65 infants born with a gestational age before 32 weeks were screened for development of ROP, 38 infants developed ROP (58%), while only 41.5% were free. ROP reported by Taquin et al[@b16-opth-11-387] study (32.4%) involved only low-birth-weight infants, while Chen et al[@b17-opth-11-387] (10.8%) study involved infants with higher gestational age and birth weight (up to 2 kg and or 34 weeks' gestational age).

In the present study, we investigate the most significant risk factors related to the development of ROP; we found that the most important risk factors included O~2~ therapy \>7 days, cesarean section (as a mode of delivery), sepsis, prolonged mechanical ventilation, blood transfusion, premature rupture of membranes (PROM), development of hypoxia due to pneumothorax, hypoxic ischemic encephalopathy, cardiac problems, and newborn jaundice. These findings were going with many other studies as Chen et al,[@b18-opth-11-387] while in Hadi and Hamdy[@b19-opth-11-387] cohort study, the risk factors for ROP were sepsis, continuous positive airway pressure, mechanical ventilation, neonatal indirect hyperbilirubinemia, intra ventricular hemorrhage, patent ductus arteriosis, and red blood cell and/or plasma transfusion. All these factors were significantly related to the occurrence of ROP and development of severe form of the disease except for indirect hyperbilirubinemia.

In our study, Apgar score in the first minute of life was mainly 4--6 (91.4%) (moderate Apgar score) and at 5 minutes was mainly \>6 (7--9) (high Apgar score); there was a high significant negative correlation between severity of ROP and Apgar score at 1 and 5 minutes of life in the patients group. This comes in agreement with Martínez-Cruz et al's[@b20-opth-11-387] study.

In our study, serum apelin was detectable in all the studied groups, which come in concordance with the study of Malamitsi-Puchner et al,[@b21-opth-11-387] who found that apelin was detectable in the serum of all studied neonates. We also evaluate the serum apelin level-1 (at birth) and level-2 (after 4--6 weeks) in both patients and control groups.

The average serum apelin level-1 is nearly equal in both patients and control groups; this comes in disagreement with Cekmez et al's[@b22-opth-11-387] study where the non-ROP (control) group had higher serum apelin level-1 than ROP (patients) group.

After 4--6 weeks, apelin level-2 was higher in non-ROP group than the ROP group, and this comes in agreement with Cekmez et al's[@b22-opth-11-387] study.

ROC curve was used to define the best cutoff value of apelin level-1 in our patients, which was 2.18, with sensitivity of 42.9%, specificity of 80%, positive predictive value of 68.2%, negative predictive value of 58.3%, and diagnostic accuracy of 59.1%. Another (ROC) curve was used to define the best cutoff value of apelin level-2 which was 2.7, with sensitivity of 62.9%, specificity of 80%, positive predictive value of 75.9%, negative predictive value of 68.3%, and diagnostic accuracy of 71%.[@b23-opth-11-387]

High positive predictive value of serum apelin level-2 test in our study prove that apelin test can predict the ROP early and prevent loss of vision if not controlled early enough. Sensitivity might be attributed to small number of the studied patients group (sensitivity of 62.9% and specificity of 80%), yet it suggests that the role of serum apelin in ROP should be further investigated.

Geiger et al[@b24-opth-11-387] investigated the role of hypoxia on the expression of the adipokine apelin. Hypoxia in adipose tissue leads to a dysregulation of the expression of adipokines. He improved that apelin expression and secretion by human adipocytes are strongly induced under hypoxic conditions and that the early response on hypoxia with apelin induction is dependent on hypoxia-inducible factor 1-α (HIF-1α). Eyries et al[@b25-opth-11-387] also reported that apelin is a hypoxia-inducible gene by both in vitro and in vivo studies. They found that hypoxia-induced apelin expression was mediated by HIF through a hypoxia-response element located within the first intron of the gene. Moreover, they determined that hypoxic induction of apelin expression regulated endothelial proliferation. Concerning the relationship between apelin and VEGF, they reported that apelin could enhance endothelial cell proliferation and aggregation in the presence of VEGF.[@b26-opth-11-387],[@b27-opth-11-387]

Lim et al's[@b28-opth-11-387] study reported that human preterm and term labor significantly decreased apelin gene expression, but had no effect on APJ expression. They suggested an important role for apelin and APJ in the regulation of placental flow and vasculogenesis. The result of Zhang et al[@b29-opth-11-387] showed that both apelin and APJ were positively expressed in the fibrovascular membrane of the ROP. The results also showed that apelin stimulates migration, proliferation, and capillary-like tube formation of RF/6A cells but not human umbilical venous endothelial cells and that apelin promotes angiogenesis in vivo. Therefore, they conclude that apelin/APJ signals seem to serve as a stimulatory factor in angiogenesis, probably in retina. Cekmez et al[@b22-opth-11-387] used other tests (with serum apelin level test) to detect serum IGF-1 to aid early detection of ROP -- it improved that circulating apelin concentrations in preterm babies may be linked with ROP like IGF-1 levels -- while Lofqvist et al[@b30-opth-11-387] used postnatal weight gain and serum IGF-1 for early detection of ROP.

Conclusion
==========

Serum apelin was found to be of significant diagnostic value in the occurrence of ROP. Serum apelin values were significantly lower in patients group compared with controls group as regards ROP. There is also a significant positive correlation between the use of oxygen therapy \>7 days and the severity of the ROP. The best cutoff value of serum apelin to detect ROP (after 4--6 weeks) was (2.7 ng/mL) with a sensitivity of 62.9% and specificity of 80%. Further studies are needed to 1) declare if serum apelin levels get affected by other diseases, such as respiratory distress syndrome, hemorrhagic diseases, or surgical conditions, and in neonates 2) consolidate the value of serum apelin in management of neonates admitted to NICU with ROP as a predictive marker.
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![Interactive dot diagram between patients and control groups as regards serum apelin levels at birth.\
**Notes:** The best cutoff value was 2.18 ng/mL, with a sensitivity of 42.9% and a specificity of 80%. 1= patients; 0= control.](opth-11-387Fig2){#f2-opth-11-387}

![ROC curve between patients and control groups as regards serum apelin levels, at 4--6 weeks of age.\
**Abbreviation:** ROC, receiver operating characteristic.](opth-11-387Fig3){#f3-opth-11-387}

![Interactive dot diagram between patients and control groups as regards serum apelin at 4--6 weeks of age.\
**Notes:** The best cutoff value was 2.7 ng/mL, with a sensitivity of 62.9% and a specificity of 80%. 1= ROP; 0= non-ROP.\
**Abbreviation:** ROP, retinopathy of prematurity.](opth-11-387Fig4){#f4-opth-11-387}

###### 

Demographic characteristics of studied groups

  Variables                 ROP group (n=38)   Non-ROP (n=27)   Test of significance   *P*-value
  ------------------------- ------------------ ---------------- ---------------------- -----------
  Gender, n (%)                                                                        1.000
   Female                   18 (47.4)          11 (40.8)        *χ*^2^=0.000           
   Male                     20 (52.6)          16 (59.2)                               
  Gestational age (weeks)                                                              0.467
   X ± SD                   30.37±1.29         31.14±1.33       *t*=0.534              
   Range                    28--32             28--32                                  
  Birth weight (kg)                                                                    0.197
   X ± SD                   1.42±0.54          1.58±0.48        *t*=1.696              
   Range                    987--1,205         1,015--1,227                            

**Notes:** *t*= Student's *t*-test, *χ*^2^= chi-square test, *P*\>0.05: nonsignificant.

**Abbreviations:** X ± SD, mean ± standard deviation; ROP, retinopathy of prematurity.

###### 

Correlation between ROP and some risk factors among patients group

  Variables                Stages of ROP (n=38)   *χ*^2^      *P*-value            
  ------------------------ ---------------------- ----------- ----------- -------- --------------
  Apgar score (at 5 min)                                                           \<0.001 (HS)
   4--6 (n=3)              0 (0.0%)               0 (0.0%)    3 (100%)    25.430   
   7--10 (n=32)            23 (71.9%)             8 (25%)     1 (3.1%)             
  Mode of delivery                                                                 0.144 (NS)
   CS (n=25)               14 (56%)               7 (28%)     4 (16%)     3.869    
   Vaginal (n=10)          9 (90%)                1 (10%)     0 (0.0%)             
  PROM                                                                             0.102 (NS)
   Negative (n=28)         16 (57%)               8 (29%)     4 (14%)     4.565    
   Positive (n=7)          7 (100%)               0 (0.0%)    0 (0.0%)             
  O~2~ therapy                                                                     0.039 (S)
   \<7 days (n=3)          3 (100%)               0 (0.0%)    0 (0.0%)    5.902    
   \>7 days (n=32)         20 (62.5%)             8 (25%)     4 (12.5%)            
  MV                                                                               0.425 (NS)
   Negative (n=20)         16 (80%)               4 (20%)     0 (0.0%)             
   Positive (n=15)         7 (47%)                4 (26.5%)   4 (26.5%)   1.712    
  Pneumothorax                                                                     0.374 (NS)
   Negative (n=26)         17 (65%)               7 (27%)     2 (8%)      1.968    
   Positive (n=9)          6 (67%)                1 (11%)     2 (22%)              0.252 (NS)
  Sepsis                                                                           
   Negative (n=13)         10 (77%)               3 (23%)     0 (0.0%)    2.759    
   Positive (n=22)         13 (59%)               5 (23%)     4 (18%)              
  Blood transfusion                                                                0.977 (NS)
   Negative (n=27)         18 (67%)               6 (22%)     3 (11%)              
   Positive (n=8)          5 (62.5%)              2 (25%)     1 (12.5%)   0.048    
  Neonatal jaundice                                                                0.558 (NS)
   Negative (n=28)         18 (64%)               6 (21%)     4 (15%)     1.168    
   Positive (n=7)          5 (71%)                2 (29%)     0 (0.0%)             
  Perinatal asphyxia                                                               0.192 (NS)
   Negative (n=34)         23                     8           3           4.978    
   Positive (n=1)          0                      0           1                    

**Notes:** *χ*^2^= chi-square test, *P*\<0.05: significant, *P*\>0.05: nonsignificant, *P*\<0.001: highly significant.

**Abbreviations:** ROP, retinopathy of prematurity; CS, c-section; PROM, premature rupture of membranes; MV, mechanical ventilation; S, significant; NS, nonsignificant; HS, highly significant; min, minutes.

###### 

Serum apelin levels at birth and 4--6 weeks among the studied groups

  Serum apelin levels             ROP group   Non-ROP group   *t*     *P*-value
  ------------------------------- ----------- --------------- ------- ---------------------------------------------------
  Serum apelin at birth (ng/mL)                                       0.313
   Range                          1.4--2.4    2--2.6          1.032   
   X ± SD                         1.5±0.6     1.8±0.4                 
  Apelin at 4--6 weeks (ng/m L)                                       0.024[\*](#tfn5-opth-11-387){ref-type="table-fn"}
   Range                          1.6--2.7    2.5--3.9        5.312   
   X ± SD                         1.7±0.8     2.9±0.4                 

**Notes:**

*P*\<0.05: significant difference *t*= Student's *t*-test. A comparison of mean levels of serum apelin between the groups of patients and controls was undertaken. At the sampling time at birth, there were no significant differences between respective mean values in the two groups (*P*\>0.05). Measurements made at 4--6 weeks after birth showed higher mean concentrations of serum apelin in patients (*P*\<0.05).

**Abbreviations:** ROP, retinopathy of prema turity; X ± SD, mean ± standard deviation.
